Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-ascending-dose and infusion-rate crossover study of Lu AF90103 in healthy men
NL-OMON50833Phase 1Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Jun 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AF90103 in major depressive disorder (MDD), sponsored by Lundbeck. Started Jun 2021; status: active, not recruiting.
02
Drugs
Lu AF90103
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON50833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50833.